GlassScriptPhysician profile
Sandip Nijjar
NPI 1215665120
$7,849.19
in general payments reported to CMS, 2019-2025
15 companies · $1,413 in 2025
The $1,413 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $845 · 2024: $5,591 · 2025: $1,413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,080 · Honoraria: $2,500 · Travel and Lodging: $2,153 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,079.51 |
| Honoraria | $2,500.00 |
| Travel and Lodging | $2,153.41 |
| Education | $116.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $5,366.21 | 2024-2025 | Voquezna |
| Abbvie INC. | $480.36 | 2023-2025 | |
| Janssen Biotech, INC. | $399.62 | 2024-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $325.43 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $306.53 | 2023 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $229.47 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $218.01 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $180.86 | 2024-2025 | Entyvio, Eohilia |
| Celgene Corporation | $113.55 | 2023 | Zeposia |
| Exact Sciences Corporation | $55.20 | 2023 | Cologuard Collection Kit |
| Pfizer INC. | $43.76 | 2024-2025 | |
| Vivus LLC | $38.49 | 2024 | Pancreaze |
| Novo Nordisk INC | $32.27 | 2025 | |
| Currax Pharmaceuticals LLC | $30.05 | 2023 | Contrave, Onzetra Xsail |
| Merck Sharp & Dohme LLC | $29.38 | 2024 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandip Nijjar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.